Syncona β Full Portfolio
35 tracked investments Β· listed companies and verified rows first
Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
London
Martin PulΓ©(Senior Vice President, Founder, Chief Scientific Officer)Christopher Williams(Senior Vice President, Chief Business Development Officer)Edgar Braendle(Executive Officer)inChristopher Vann(Executive Officer)inDavid Brochu(Executive Officer)inChristian Itin(Chief Executive Officer and Director)in
Co-investorsNextech Invest
Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.
BiotechDigital HealthMedical Devices
Daniel Chung(Chief Medical Officer)inLance Baldo(Chief Executive Officer)inAbraham Scaria(Chief Scientific Officer)in
Co-investorsAdvent Life SciencesForbionOxford Science EnterprisesTCG Crossover
Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).
BiotechHealthtechMedical Devices
John
Co-investorsRoche Venture Fund
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.
BiotechDeep TechHealthtechMedical Devices
Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in
Co-investorsInkef3B Future Health FundM VenturesVI PartnersXGEN Venture
OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.
BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB
Professor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)Idlir Liko(Founder)inJonathan Hopper(Vice President, Platforms and Founder)inHsin Yung (Jason) Yen(Founder)inRos Deeganin
Co-investorsGV (Google Ventures)Oxford Science EnterprisesSanofi VenturesNorthpond Ventures
Spur Therapeutics develops gene therapy treatments for genetic diseases, aiming to bring genetic medicine therapies to patients worldwide.
BiotechDigital HealthHealthtechMedical Devices
BoardChris(Chair (until August 2026), Chief Executive Officer)
Co-investorsAlbionVCUCL Technology Fund
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Board seatRoel BulthuisΒ· per SEC Form D Β· $85M raise Β· filed Jun 2022
Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundNextech InvestInkefRA Capital
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Board seatElisa PetrisΒ· per SEC Form D
Co-investorsEcoR1 CapitalJeito CapitalVida VenturesTPG
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Board seatRoel BulthuisΒ· per SEC Form D
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+8 more
Quell Therapeutics is a clinical-stage biopharmaceutical company developing targeted Treg cell therapies with advanced manufacturing capabilities.
BiotechDeep TechHealthtechMedical Devices
Co-investorsAlbionVCJeito CapitalSV Health InvestorsUCL Technology Fund
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.
BiotechBasel, CH
Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in
Co-investorsNovartis Venture FundPfizer Venture InvestmentsPontifax Venture Capital
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsBain Capital Life SciencesCasdin CapitalLifeSci Venture PartnersVenrock Healthcare Capital Partners
Cambridge, US
ENEJ KUSCER, PH.D.(Executive Officer)PETER VAN VLASSELAER, PH.D.(Director)HENRIJETTE RICHTER, PH.D.(Director)BERNARDUS MACHIELSE(Director)LUCAS DE BREED(Director)DAVID DE GRAAF, PH.D.(Executive Officer, Director)
Co-investorsMission BiocapitalCanaan PartnersSofinnova Partners
Novartis is a pharmaceutical company that develops and commercializes prescription medicines and therapies across therapeutic areas including oncology, cardiovascular disease, and immunology.
BiotechMedical Devices
Co-investorsCambridge Innovation CapitalSofinnova Ventures
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsJeito CapitalNovo HoldingsRoche Venture FundInkef
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.
BiotechDigital HealthHealthtechMedical Devices
Moin Saleem(Co-founder & Chief Scientific Advisor)in
Co-investorsSofinnova PartnersForbionGilde HealthcareAdvent Life SciencesBritish Patient Capital
Resolution develops a macrophage cell therapy to treat end-stage liver disease, aiming to reduce the need for liver transplantation and improve patient outcomes.
BiotechHealthtechMedical Devices
Neuromodulation therapy for migraine relief.
Co-investorsInnovation IndustriesDolby Family VenturesInkef
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter ReitsmainJohn Glasspool(Chief Executive Officer)in
Co-investorsSound BioventuresYsios CapitalBioGeneration VenturesEICEQT Life SciencesInkef+3 more
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Gyroscope Therapeutics LtdPronutria Biosciences14MGAutolusAzeria TherapeuticsBeacon TherapeuticsBlue EarthContentKesmalea TherapeuticsMosaic TherapeuticsNightstarPortfolio dataQuell TherapeuticsRe-Aim TherapeuticsSlingshot TherapeuticsYellowstone Biosciences
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.